Summer Davos spotlight falls on host city Dalian's economic rise

Summer Davos spotlight falls on host city Dalian's economic rise

DALIAN, China, June 23, 2026 /PRNewswire/ -- A news report from China Daily: An elevated view of Dalian. The World Economic Forum's 17th Annual Meeting of the New Champions, aka the Summer Davos, is being held in Dalian from June 23 to 25,...

Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall

Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall

From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases PHILADELPHIA, June 22, 2026 /PRNewswire/ -- During the DIA Global Annual Meeting 2026 held in Philadelphia,...

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug...

Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio

Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio

HONG KONG, June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for...

TTM+ 2026 opens in Pattaya advancing sustainable and wellness-led tourism

TTM+ 2026 opens in Pattaya advancing sustainable and wellness-led tourism

Thailand's largest travel trade event connects global buyers and Thai sellers through "Healing is the New Luxury" with responsible tourism, wellness and sustainability at its core PATTAYA, Thailand, June 11, 2026 /PRNewswire/ -- The Tourism...

Aurora Energy Accelerates ERP Modernisation with Dynamics 365 and Hitachi Solutions Asia Pacific

Aurora Energy Accelerates ERP Modernisation with Dynamics 365 and Hitachi Solutions Asia Pacific

Government–owned energy retailer modernises legacy systems with a cloud–based ERP to strengthen compliance, efficiency, and data–driven decision–making. SYDNEY, June 10, 2026 /PRNewswire/ -- Aurora Energy, a government owned electricity retailer...

BenQ at COMPUTEX 2026: Advancing AI Transformation Through Specialized Experiences and Human-Centric Innovation

BenQ at COMPUTEX 2026: Advancing AI Transformation Through Specialized Experiences and Human-Centric Innovation

Showcasing how AI, digital transformation, and purpose-built solutions empower professionals across education, enterprise, creative, gaming, and immersive environments TAIPEI, June 3, 2026 /PRNewswire/ -- At COMPUTEX 2026, BenQ showcases how...

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease

Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease

SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European...

SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies

SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies

SHANGHAI, May 27, 2026 /PRNewswire/ -- SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in Cell with...

TXOne Networks' Nasser Zayour on Why Execution, Not Visibility, Will Define the Next Phase of OT Security

TXOne Networks' Nasser Zayour on Why Execution, Not Visibility, Will Define the Next Phase of OT Security

TAIPEI, May 27, 2026 /PRNewswire/ -- OT security is entering a new phase. While industrial organizations have significantly improved visibility into their environments, many still struggle to reduce risk without disrupting operations. In an...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 20
  • menu
    menu